JP2022536692A5 - - Google Patents
Info
- Publication number
- JP2022536692A5 JP2022536692A5 JP2021573442A JP2021573442A JP2022536692A5 JP 2022536692 A5 JP2022536692 A5 JP 2022536692A5 JP 2021573442 A JP2021573442 A JP 2021573442A JP 2021573442 A JP2021573442 A JP 2021573442A JP 2022536692 A5 JP2022536692 A5 JP 2022536692A5
- Authority
- JP
- Japan
- Prior art keywords
- raav vector
- vector according
- raav
- promoter
- plasma kallikrein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860101P | 2019-06-11 | 2019-06-11 | |
| US62/860,101 | 2019-06-11 | ||
| PCT/US2020/037189 WO2020252136A1 (en) | 2019-06-11 | 2020-06-11 | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536692A JP2022536692A (ja) | 2022-08-18 |
| JP2022536692A5 true JP2022536692A5 (cg-RX-API-DMAC7.html) | 2023-06-20 |
Family
ID=71995023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573442A Pending JP2022536692A (ja) | 2019-06-11 | 2020-06-11 | 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230038502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983449A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022536692A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114207135A (cg-RX-API-DMAC7.html) |
| AR (1) | AR119271A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202115126A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020252136A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| US20250326861A1 (en) * | 2020-09-15 | 2025-10-23 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| CN114790245B (zh) * | 2021-01-25 | 2026-08-11 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| AU2022214914A1 (en) * | 2021-01-28 | 2023-08-17 | Astria Therapeutics, Inc. | Plasma kallikrein antibodies and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| EP1737966B1 (en) | 2004-04-02 | 2012-05-09 | Board of Regents, The University of Texas System | Cancer specific promoters |
| US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達 |
| GB201206455D0 (en) | 2012-04-12 | 2012-05-30 | Royal Holloway & Bedford New College | Gene expression |
| US9346872B2 (en) * | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| AU2014228765A1 (en) | 2013-03-15 | 2015-10-15 | Medimmune, Llc | Palivizumab epitope-based virus-like particles |
| IL247942B (en) * | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| JP6754361B2 (ja) | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| CL2014003590A1 (es) | 2014-12-30 | 2015-07-10 | Univ Chile | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje. |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| JP6879486B2 (ja) * | 2015-03-17 | 2021-06-02 | フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel | Fviiiおよびfix用の最適化された肝臓特異的発現系 |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| GB2547179A (en) | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| US10190135B2 (en) | 2015-10-27 | 2019-01-29 | Celltheon Corporation | Chimeric post-transcriptional regulatory element |
| AU2017248259A1 (en) | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| CN109844124B (zh) | 2016-05-20 | 2023-10-03 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| ES3024357T3 (en) | 2017-02-17 | 2025-06-04 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| TWI753168B (zh) * | 2017-05-22 | 2022-01-21 | 日商武田藥品工業股份有限公司 | 用於血友病b基因療法之編碼具有增強表現的重組fix變異體之病毒載體 |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
-
2020
- 2020-06-11 US US17/618,193 patent/US20230038502A1/en not_active Abandoned
- 2020-06-11 TW TW109119759A patent/TW202115126A/zh unknown
- 2020-06-11 AR ARP200101656A patent/AR119271A1/es unknown
- 2020-06-11 CN CN202080055596.9A patent/CN114207135A/zh active Pending
- 2020-06-11 EP EP20753482.7A patent/EP3983449A1/en not_active Withdrawn
- 2020-06-11 WO PCT/US2020/037189 patent/WO2020252136A1/en not_active Ceased
- 2020-06-11 JP JP2021573442A patent/JP2022536692A/ja active Pending